Data as of Jan 23
| -0.04 / -1.79%|
The 5 analysts offering 12-month price forecasts for CTi Biopharma Corp have a median target of 6.00, with a high estimate of 6.50 and a low estimate of 3.00. The median estimate represents a +173.97% increase from the last price of 2.19.
The current consensus among 5 polled investment analysts is to Buy stock in CTi Biopharma Corp. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.